It is not what posters on this board think, because you need to go back and verify that what happened in the past. I have observed for the last several years that the SP has not moved on predictions made by posters on this board You need a thorough knowledge of ALL factors that affect SP which is not manifested by any one posting on this board, including myself. Just keep visiting the company web site and interpret news based on facts to get an idea of what really needs to happen to lift the SP. Do not ignore what is going on in the entire biotech industry and seek its relevance to Geron.
The circumstance has to be appropriate, and visualized by right parties. This board is not the platform on which that appropriateness is determined though!!!
Having got burned, he is here for just fun!! He will quit when a SP jump throws him off the fake cliff he is dreaming about!!
Yes, insignificant, invisible humans carry ego a zillion times greater than their celestial size. It's like an overblown balloon!! And, yet the idiots think they run everything in this universe!!
The hedge funds use programmed trading through their independently developed software based on algorithm that ties their secret chart techniques with other boundary conditions. When certain prespecified conditions are reached, trading automatically takes place. Therefore, often, it appears to us that someone is deliberately manipulating. This the vermin can't comprehend. Therefore, they act like monkeys. These lazy bums want to make money without sweating and have no brain to comprehend company fundamentals or developments. All retail traders use shoot-in-the dark techniques and some times they make money; but often loose. Yet, these idiots can't learn their lesson through their own experience and like dumbaxxssexxs get back to their habit over and over!!.
Yes, and the FDA can stall the entire process, depending on how much pull you have with the guys in control there. This process is thus an indeterminate factor!!
Wnderful!! Do the vermin know what they are doing? Lazy bums can't part with their habit!!!
Jack, I think you are missing my point. I was trying to tie the IMET efficacy to genetic history of a patient and its relationship to mutation of genes causing the cancer development. Isn't it why only 4 out of some 30+ patients tried at Mayo got CR, and some PR, but a majority did not? Yes some had CI. My point is that the effect was varied, depending on the patient, isn't it? If this was just for MF patients, how the same or similar underlying reason(s) will affect multi-applications of IMET? Of course, there is no drug at present that gets what IMET gets; but, before the FDA licenses any drug it WIL require qualifying conditions to be clarified for clinical use of the prescribing physician. All I meant that this clarification process will be time consuming and will not happen so quickly because it will need a lot of study and sufficiently long-term observations.
Jack, I have given my thumb up!! Thanks for your well-studied posts.
You have to realize that standing alone Geron had to come up for not only money but also an organization that can efficiently handle licensing and commercial production, marketing, distribution, etc. of a BTD product. This would have taken a much longer time and a lot of headache raising needed money and fulfilling the FDA requirements in time. Time and expediency are very important in development of such a drug to realize successful commercialization because someone else will come up with a competing product soon and you will loose not only the market but also the glory that goes with being the "first of its kind". Furthermore, the MF trial is just a first application of IMET, it has excellent potential for multi applications for which a lot of studies and efforts will be needed to bring it to fruition. Considering all these factors and reasons, the collaboration with Janssen is certainly a welcome step the management has taken. From the investor point of view, it will be good too because you will see growth of your investment not only faster but also significantly more secure.
I think once IMET gets license for MF, it will be a lot easier to try it as an orphan drug for applications to other cancers and thereby collect requisite data, especially for conjugate use. Therefore, in my view, Geron must concentrate first on getting the FTD or BTD status approval from the FDA for the MF trial. That's perhaps what they may be trying to do too.
Jack, yes your posts indicate that you have background and knowledge that none on this board may have; however, I believe that IMET efficacy and that of modifications for applicability to solid tumors must be dependent on the genetic background that caused the mutations resulting in the malfunction. These studies may have been in progress and the ultimate results would show that the efficacy varies with the genes that caused the mutation. The question then would be: How to modify or develop IMET that works well for more common gene mutations with a stand-alone use and similarly in combination with other appropriate drug(s) for the other mutations. These are pretty tough and time-consuming studies and, hence, any expectation of quick approval of multi applications is just a dream. I am not a cell physicist nor a biology major; and my understanding is incomplete; but, I see it clearly that there is a long way to go still in that arena. Surely, J&J and Mayo associations are crucial in that sense and also to keep the FDA continually on Geron's side. Being patient is the buzz word!!
Black, the Veil Of Silence may have been imposed by the board!! Perhaps on the basis of secrecy that may have been required due to sensitivity of issues under progress. I am sure things will open up gradually when the time is appropriate.
Shorts are just mushrooming like vermin!! This board is just a worthless platform to find any post you want to spend even a second to look at!!
These new developments (Sienna's interest in the bladder- cancer diagnosis, IMET's hold lift, and potential new applications of IMET and its modifications for general applications to all cancers - all of these based on the telomere-telomerase concept) should make Geron a household name in the cancer arena and, hence, Geron's merger or acquisition by J&J should bring Geron shareholders decent return on their investment. This all started after Tefferi/Mayo came on board!! To get Tefferi/Mayo to do the MF trial, thus, was a landmark decision, isn't it?!